Veverimer

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581949

CAS#: 2099678-27-8

Description: Veverimer is used in treatment of Metabolic Acidosis Associated with Chronic Kidney Disease.


Price and Availability

Size
Price

Size
Price

Size
Price

Veverimer is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 581949
Name: Veverimer
CAS#: 2099678-27-8
Chemical Formula: (C9-H18-N2)x.(C3-H7-N)y.(C2-H4-Cl2)z
Exact Mass:
Molecular Weight: 310.3101
Elemental Analysis:


Synonym: Veverimer; veverimerum; TRC101; WHO 11162; UNII-10VSMQY402.

IUPAC/Chemical Name: 1,3-Propanediamine, N1,N3-di-2-propen-1-yl-, polymer with 1,2-dichloroethane and 2-propen-1-amine


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.90.01


References

1: Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, Klaerner G, Bushinsky DA. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. Lancet. 2019 Aug 3;394(10196):396-406. doi: 10.1016/S0140-6736(19)31388-1. Epub 2019 Jun 24. PubMed PMID: 31248662.

2: Chen W, Abramowitz MK. Advances in management of chronic metabolic acidosis in chronic kidney disease. Curr Opin Nephrol Hypertens. 2019 Sep;28(5):409-416. doi: 10.1097/MNH.0000000000000524. PubMed PMID: 31232712; PubMed Central PMCID: PMC6677263.

3: Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, Klaerner G, Bushinsky DA. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial. Lancet. 2019 Apr 6;393(10179):1417-1427. doi: 10.1016/S0140-6736(18)32562-5. Epub 2019 Mar 8. PubMed PMID: 30857647.

4: Bushinsky DA, Hostetter T, Klaerner G, Stasiv Y, Lockey C, McNulty S, Lee A, Parsell D, Mathur V, Li E, Buysse J, Alpern R. Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD. Clin J Am Soc Nephrol. 2018 Jan 6;13(1):26-35. doi: 10.2215/CJN.07300717. Epub 2017 Nov 4. Erratum in: Clin J Am Soc Nephrol. 2019 Jan 10;:. PubMed PMID: 29102959; PubMed Central PMCID: PMC5753317.